Why CVRx, Inc.’s (CVRX) Stock Is Down 6.13%
As of Friday, July 31, CVRx, Inc.’s CVRX share price has dipped by 6.13%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Commentary & Analysis
Why CVRx, Inc.’s (CVRX) Stock Is Down 5.57%
As of Friday, July 17, CVRx, Inc.’s CVRX share price has dipped by 5.57%, which has investors questioning if this is right time to buy.Jenna Brashear
Why CVRx, Inc.’s (CVRX) Stock Is Up 6.26%
As of Thursday, July 16, CVRx, Inc.’s CVRX share price has surged by 6.26%, which has investors questioning if this is right time to sell.Jenna Brashear
Why CVRx, Inc.’s (CVRX) Stock Is Down 5.62%
As of Tuesday, July 14, CVRx, Inc.’s CVRX share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Michael Rose
Why CVRx, Inc.’s (CVRX) Stock Is Down 6.27%
As of Wednesday, July 08, CVRx, Inc.’s CVRX share price has dipped by 6.27%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | CVRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $142.8 | $334.8 | 24% |
|
| Shares Out (Mil) | 26.4 | 41.7 | 35% |
|
| Institutional Ownership | 97.8% | 77.3% | 76% |
|
| Float (Mil) | 18.3 | 34.7 | 27% |
|
| Beta | 0.78 | 0.86 | 46% |
|
| Avg Daily Volume (000s) | 225 | 266 | 46% |
|
| Price Change (52-week) |
(34.9%) | 60.7% | 22% |
|
| Growth | CVRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 56.2% | 11.8% | 97% |
|
| Net Income (5yr) | (30.5%) | (5.8%) | 13% |
|
| EPS (5yr) | 44.0% | 10.7% | 90 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (16.1%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.524) | ($1.963) | ($1.894) | |
| Month Ago EPS | ($0.524) | ($1.963) | ($1.894) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.518) | ($1.976) | ($1.869) | |
| Year/Year Chg | 5.2% | (4.0%) | (18.4%) | |
| Financials | CVRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $59 | $152 | 22% |
|
| Net Income (TTM) (Mil) | ($53) | ($11) | 16% |
|
| EPS (TTM) | ($2.010) | ($0.500) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($40) | ($2) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($30) | $1 | 23% |
|
| Long-Term Debt (Q1) (Mil) | $59 | $22 | 40% |
|
| Enterprise Value (Q1) (Mil) | $131 | $304 | 23% |
|
| Valuation | CVRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.89 | 2.88 | 78% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | CVRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.2% | 59.1% | 92% |
|
| Net Margin | (89.1%) | (7.7%) | 8% |
|
| ROA | (45.9%) | (13.7%) | 13% |
|
| ROE | (107.0%) | (15.9%) | 9% |
|
| Liabilities to Assets | 70.8% | 44.9% | 66% |
|
| F-Score | 4 | 4 | 34% |
|
CVRx, Inc. did not pass any screens on 7/30/2026.
